Elicera Therapeutics Q1: Positive pattern emerging in CARMA trial - Redeye

Redeye returns with an updated view following Elicera’s Q1 report and encouraging data from the phase I/II CARMA study, evaluating ELC-301 in diffuse large B-cell lymphoma (DLBCL). Based on the positive clinical signals, we have raised our assumptions related to the likelihood of approval and potential deal terms for ELC-301. In addition, we have lowered the WACC in accordance with Redeye’s revised rating model. These changes result in a higher valuation range.

Länk till analysen i sin helhet: https://www.redeye.se/research/1112974/elicera-therapeutics-q1-positive-pattern-emerging-in-carma-trial?utm_source=finwire&utm_medium=RSS